Ultragenyx In The Money As PRV Income Tops $400m
The company has sold two rare pediatric disease priority review vouchers in the space of a week.
Scrip - October 15, 2026

MHRA Will ‘Increasingly Enable’ Switch In UK, In Move Industry Says ‘Should Not Be Underestimated’
UK regulator MHRA has written enabling reclassification into its 2030 strategy, pledging risk-based prioritization of applications and better support for self-care. PAGB calls the move “an important opportunity.”
HBW Insight - October 15, 2026

Execs On The Move: October 5–9, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - October 15, 2026

Murphy Steps Down As FDA’s OGD Director Amid ‘Political Pressure,’ Admin Burden
Iilun Murphy decided to step down as Office of Generic Drugs director for an associate director position, another senior leadership change under the Trump administration.
Generics Bulletin - October 15, 2026

Accord Builds On US Portfolio Dream With Filgrastim Biosimilar Launch
Accord’s goal of commercializing 20 US biosimilars by 2030 is a step closer with the latest biosimilar launch of Filkri (filgrastim-laha). However, the firm enters a mature and established filgrastim biosimilars market.
Generics Bulletin - October 15, 2026

Alvotech And Advanz Are First To Take Aim At Eylea HD
Partners Alvotech and Advanz Pharma have claimed pole position globally with their filing for a high-dose aflibercept 8mg biosimilar in Europe, based on Regeneron’s Eylea HD.
Generics Bulletin - October 15, 2026

Genfleet/Verastem Eye World-First Phase III Trials For KRAS G12D Inhibitor In CRC
Partners separately announce strong Phase I data and Phase III plans for GFH375 (VS-7375), an oral KRAS G12D (ON/OFF) inhibitor, for colorectal cancer in and outside of China.
Scrip - October 15, 2026

Beyond The Base Case: Why Biosimilar Companies Need Two Forecasting Engines, Not One
Biosimilar bets are forecasts built on a forecast: estimate the originator's value at LOE a decade out, while the molecule is still gaining indications and facing new competition, then project your own launch on top. The industry's instinct is one tidy framework. The two problems are not the same.
In Vivo - October 15, 2026

Picking The Wrong Biosimilar Costs A Decade, Not A Quarter
Biosimilar developers must value someone else's molecule a decade out, then forecast their own share of it. Currently the industry uses one instrument for both jobs. When the case is tested against the record: the diagnosis holds, the prescription is untested.
In Vivo - October 15, 2026

OMass Aims To Be ‘Britain’s Big Biotech’
As the Oxford-headquartered firm raises $310m, CEO Ros Deegan tells Scrip about its hopes to produce a broad pipeline across endocrinology and immunology.
Scrip - October 15, 2026

Bausch + Lomb’s Few Words On CEO Change Leave Questions About FDA Warning Unanswered
Brent Saunders apparently wasn’t a cog in B+L’s confidence in expecting to increase its full-year guidance. Canadian firm marketing OTC eye drops Biotrue, Blink, Lumify and Soothe in US also didn’t note it was working on an acquisition.
HBW Insight - October 15, 2026

BEMT Could Move SPF In US From Beach Bag To Daily Routine – DSM-Firmenich
Dsm-firmenich’s Carl D’Ruiz explains during an Oct. 14 webinar how BEMT is enabling US formulators to make more creative and lighter sunscreens, as the Swiss-Dutch ingredients and innovation company launches its RADIANCE & GLOW face and lip collection with the active.
HBW Insight - October 15, 2026